Compugen (CGEN) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Compugen Ltd. has secured a new U.S. patent for its innovative cancer treatment approach, involving the combination of its COM902 antibody with anti-PD-1 and anti-PVRIG antibodies. This patent strengthens Compugen’s intellectual property portfolio in the field of DNAM-1 axis checkpoint inhibitors, potentially enhancing shareholder value. The patent is part of Compugen’s strategy to develop advanced cancer immunotherapies and is valid until at least 2037.
For further insights into CGEN stock, check out TipRanks’ Stock Analysis page.